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Abstract (247 words) 
 
The maintenance of muscle size and fiber composition requires contractile activity. 
Increased activity stimulates expression of the transcriptional coactivator PGC-1α which 
promotes fiber-type switching from glycolytic towards more oxidative fibers.  In 
response to disuse or denervation, but also in fasting and many systemic diseases, 
muscles undergo marked atrophy through a common set of transcriptional changes.  The 
FoxO family of transcription factors plays a critical role in this loss of cell protein, and 
when activated, FoxO3 causes expression of the atrophy-related ubiquitin ligases, 
atrogin-1 and MuRF1, and profound loss of muscle mass. To understand how exercise 
might retard muscle atrophy, we investigated the possible interplay between PGC-1α and 
the FoxO family in regulation of muscle size. Rodent muscles showed a large decrease in 
PGC-1α mRNA during atrophy induced by denervation as well as by cancer cachexia, 
diabetes, and renal failure. Furthermore, in transgenic mice overexpressing PGC-1α, 
denervation and fasting caused a much smaller decrease in muscle fiber diameter and a 
smaller induction of atrogin-1 and MuRF1 than in control mice. Increased expression of 
PGC-1α also increased mRNA for several genes involved in energy metabolism whose 
expression decreases during atrophy.  Transfection of PGC-1α into adult fibers reduced 
the capacity of FoxO3 to cause fiber atrophy, and to bind to and transcribe from the 
atrogin-1 promoter. Thus, the high levels of PGC-1α in dark and exercising muscles can 
explain their resistance to atrophy, and the rapid fall in PGC-1α during atrophy should 




The mass and functional capacity of skeletal muscle are tightly regulated by contractile 
activity, nutrient supply and hormones (1). Contractile activity is necessary for postnatal 
muscle growth and for the maintenance of muscle mass in adults, and increased work can 
cause fiber hypertrophy (2).  Conversely, disuse or denervation causes rapid atrophy (3).  
Skeletal muscle also serves as the organisms major protein reservoir from which amino 
acids can be mobilized for gluconeogenesis, new protein synthesis or as an energy 
store(4).  Consequently, upon food deprivation and in many systemic disease states, 
including sepsis, cancer, burn injury, diabetes, cardiac and renal failure, there is a 
generalized muscle wasting, which results primarily from increased breakdown of muscle 
proteins, although protein synthesis also falls in most of these conditions (5). In all these 
systemic catabolic states, the loss of muscle mass involves a common pattern of 
transcriptional changes, including induction of genes for protein degradation and 
decreased expression of various genes for growth-related and energy-yielding processes 
(5-7).  We have termed this group of co-ordinately regulated genes, ‘atrogenes’. Recent 
work indicates that the same transcriptional program occurs during atrophy induced by 
denervation and disuse as occurs in these catabolic states (8).  
 
In all these types of atrophying muscles, the ubiquitin-proteasome system is activated and 
catalyzes the degradation of the bulk of muscle proteins, especially myofibrillar 
components (5). In addition, there is a dramatic (8-40 fold) induction of two muscle-
specific ubiquitin ligases, atrogin-1/MAFbx and MuRF-1, whose induction occurs prior 
to the onset of muscle weight loss (7, 9) and is necessary for rapid atrophy (10). On the 
other hand, the expression of these ubiquitin ligases and the enhancement of overall 
protein breakdown are blocked by the IGF-1/insulin/PI3K/AKT signaling pathway (11, 
12), which also activates protein synthesis and net growth of these muscles.  The key 
mediators of this catabolic response during atrophy are the FoxO family of transcription 
factors, whose activity is suppressed during growth by phosphorylation by AKT (12, 13), 
but whose expression and dephosphorylation rises in these catabolic states (7, 13).  
Activation of FoxO3 promotes the expression of atrogin-1 and other atrogenes, leading to 
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a dramatic loss of muscle mass (13).  On the other hand, when FoxO3 function is 
blocked, atrogin-1 expression and the muscle atrophy induced by fasting or 
glucocorticoids are prevented (13).  
 
The mechanisms by which contractile activity preserves muscle mass, even in the face of 
catabolic signals (14-17), has long been a mystery. Muscle wasting does not occur 
similarly in all types of muscle fibers. Upon fasting (18), exposure to glucocorticoids (19, 
20), sepsis (21), and cancer cachexia (22, 23), type II glycolytic muscle fibers show 
greater atrophy than the type I oxidative fibers. On the other hand, upon unloading or 
denervation, the fatigue-resistant, slow-contracting, dark muscles show more pronounced 
atrophy than fast-contracting, glycolytic, pale ones (24). These differences appear to be 
due to the greater activity of neurons innervating the dark muscles (19).  In fact, 
increased activity protects pale muscles from glucocorticoid-induced atrophy and disuse 
sensitizes dark muscles to this catabolic hormone (19, 25).  
 
The present studies were undertaken to clarify how exercise can retard muscle wasting, 
and why fiber types differ in their susceptibility to atrophy. One attractive possibility is 
that the effects of activity on muscle size are linked to the PGC-1 family of coactivators 
(26-28)which are the prime regulators of mitochondrial content and oxidative metabolism 
and are critical in the maintenance of glucose, lipid and energy homeostasis in muscle 
and other tissues. PGC-1α was first identified as a PPARγ-interacting protein (29) and 
subsequently two other family members, PGC-related coactivator (PRC) and PGC-1β 
were identified (reviewed in (26)). In skeletal muscle, PGC-1α functions as a critical 
metabolic sensor of motor neuron-induced calcium signaling (30-32). Its expression is 
induced by both short term and chronic exercise in rodents and humans (33, 34).  
Transgenic expression of PGC-1α in fast-twitch, glycolytic muscles promotes 
mitochondrial biogenesis and oxidative metabolism (35), and importantly, transforms the 
type IIb muscle fibers into a more oxidative phenotype. PGC-1α therefore appears to be 
an important mediator of exercise and motor-nerve activity in skeletal muscle . 
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In this study, we demonstrate that PGC-1α is an important factor opposing the effects of 
FoxO on muscle mass.  Elevated levels of PGC-1α through transgenic expression reduce  
muscle atrophy upon denervation or fasting and the atrophy-promoting effects of FoxO3 
apparently by suppressing the associated changes in transcription of key atrogenes.  
Moreover, we show that PGC-1α expression falls dramatically after denervation and in 





To investigate whether a decrease in PGC-1α activity might be important in the 
transcriptional changes during muscle wasting, we initially examined how PGC-lα levels 
might vary in different experimentally-induced rat models of atrophy that mimic major 
human diseases (7). The level of PGC-1α mRNA, as measured by real time PCR, fell 
dramatically in gastrocnemius muscles undergoing rapid atrophy caused by untreated 
streptozotocin-induced diabetes (36), cancer cachexia induced with Yoshida ascites 
hepatoma (22), and uremia induced by subtotal nephrectomy (37) (Fig 1a).  At the times 
studied, muscle protein degradation is markedly accelerated in all these conditions. 
Similarly, the loss of neural activity following section of the sciatic nerve also caused a 
sharp fall in PGC-1α expression (Fig 1b).  This marked reduction in PGC-1α mRNA 
occurred early, within the first day after operation and was maximal at 3 days (data not 
shown).  In related studies in rat, we observed a similar rapid fall in PGC-1α mRNA after 
denervation or pure disuse of the gastrocnemius muscle induced by spinal isolation (8).  
Thus, its fall preceded the large decrease in muscle mass and persisted for at least two 
weeks (Fig 1b) (8), after which time atrophy continues at a slower rate (8).   
 
Transgenic expression of PGC-1α  protects muscles against atrophy. This rapid 
suppression of PGC-1α expression in many types of atrophy suggests that the decrease in 
this coactivator might contribute to the loss of muscle mass.  To determine if PGC-1α 
affects atrophy, we used our strain of transgenic mice with muscle-specific PGC-1α 
expression (35) under the control of muscle creatine kinase (MCK) promoter. The MCK 
promoter is particularly active in glycolytic, type IIb muscle fibers (e.g. the tibialis 
anterior).  Thus, in the transgenic animals, the level of PGC-1α expression in these fibers 
resembles the high level typically seen in the soleus, which contains primarily oxidative 
type IIa and type I fibers.  Fibers from these transgenic animals have a more oxidative 
phenotype, as shown by greater content of succinic dehydrogenase and a shift from type 
IIb to type IIa and I fibers (Fig 2b, (35)).  Section of the sciatic nerve was performed in 
the transgenic and control mice.  By twelve days, the denervated tibialis anterior in wild 
type animals showed more than a 40% reduction in mean fiber diameter. This decrease 
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was mainly evident in large glycolytic type IIb fibers (Fig 2a,c). By contrast, in the 
transgenic animals, although the fibers were generally smaller, denervation of the tibialis 
anterior caused much less atrophy.  Only a 10% decrease in cross sectional area and a 
minor shift in fiber size distribution were seen (Fig 2b,c).  
 
To determine whether PGC-1α can also protect against other types of muscle wasting, we 
studied the susceptibility of muscles from these transgenic mice to fasting-induced 
atrophy, which is signaled by a fall in insulin and by glucocorticoids (38, 39) rather than 
by inactivity.  By 48h after food was removed from the cages, the tibialis muscles from 
wild type animals showed a 25% reduction in mean fiber size, in accord with prior 
findings(40).  However, the muscles of mice PGC-1α transgenic mice were relatively 
resistant to atrophy, losing only 10% of their cross sectional area (Fig 2d).  Together, 
these experiments indicate that elevated levels of PGC-1α protects muscles against 
various types of atrophy, including that induced by disuse of a specific muscle or by 
endocrine changes; thus, the fall in PGC-1α in the atrophying muscles (Fig 1) is probably 
a key factor contributing to the loss of muscle mass. 
 
PGC-1α  alters expression of key atrophy-specific genes. We have previously shown 
that various types of muscle atrophy occur through a common program of transcriptional 
changes (7, 8). Because of PGC-1α’s capacity to protect against atrophy, we investigated 
whether transgenic expression of PGC-1α blocked the induction or action of genes 
critical in the atrophy process. The expression of three atrogenes involved in protein 
breakdown, the ubiquitin ligases, MuRF1 and atrogin-1, and the lysosomal hydrolase, 
cathepsin L, are dramatically induced in atrophying muscles (7).  As shown by real-time 
PCR (Fig. 3a), mRNAs for each were strongly induced after denervation in wild type 
control mice, as described previously (8). However, the increases in mRNA for atrogin-1, 
MuRF1 and cathepsin-L upon denervation were blunted by 40% in muscles expressing 
PGC-1α transgenically.  In addition, the contralateral innervated muscles of the 
transgenic animals showed lower expression of these three genes. Interestingly, the 
activity of the MCK promoter also appears to be modulated by denervation, since in the 
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transgenic mice PGC-1α mRNA levels in the denervated muscles were lower than in the 
innervated control.  
 
Similarly, when the expression of these key atrogenes was monitored during muscle 
wasting induced by fasting, the marked induction of atrogin-1 following food deprivation 
was much smaller in the transgenic animals, and no induction of MuRF-1 was evident at 
all (Fig 3b). Since the induction of these genes appears essential for rapid atrophy (7, 10), 
the ability of PGC-1α to reduce muscle atrophy likely occurs in part by suppressing the 
transcriptional program activated in these muscles. In addition to the content of the key 
ubiquitin ligases atrogin-1 and MuRF-1, the major lysosomal protease, cathepsin L, 
which also contributes to the loss of muscle protein ((41); Zhao et al, in preparation; 
Mammacuri, in preparation) is regulated similarly. 
 
Expression of a variety of genes for enzymes important in glycolysis and oxidative 
phosphorylation are suppressed co-ordinately in many forms of muscle wasting  
including lactic dehyrodrogenase, malate dehydrogenase, pyruvate dehydrogenase E2 
component, oxoacid CoA transferase, mitochondrial creatine kinase II, NADH 
dehydrogenase (ubiquinone) FeS protein 1, NADH dehydrogenase (ubiquinaone) 
flavoprotein 2, and NADH dehydrogenase (ubiquinone) 1 Beta subcomplex 5 (7, 8).  In 
microarrays from skeletal muscles of mice lacking PGC-1α, we found that 53% (nine) of 
these atrogenes were also suppressed compared with wild type animals (data not shown). 
We also measured the expression of these genes by real time PCR in the denervated and 
contralateral innervated PGC-1α transgenic animals (Fig. 3c). In each case, the mice 
producing PGC-1α transgenically had higher levels of these mRNAs.  Their expression 
fell following denervation, but still remained significantly higher than in controls. 
Together, these findings strongly suggest that the suppression of PGC-1α expression may 
underlie many of the transcriptional changes found in atrophying muscle, especially the 
decreased transcription of genes for ATP production. 
 
Interestingly, the expression of several genes that may promote protein synthesis at the 
translational level, e.g. initiation factor α2 (E1Fα2), the ribosomal protein S5, and both 
 9 
arginine and glutamine tRNA synthase, also decreased during denervation atrophy, but 
were increased in the PGC-1α transgenic mouse (Fig 3d).  Although overall rates of 
protein synthesis are not significantly altered after denervation (42) or by PGC-1α 
expression in cultured myotubes (data not shown), these observations are further 
evidence that the fall in PGC-1α production helps determine the pattern of transcriptional 
changes seen during atrophy. 
 
 
PGC-1α  reduces FoxO3-dependent transcription of atrogin-1 and muscle atrophy.  
Since mRNAs for key atrogenes including atrogin-1 was suppressed in the PGC-1α-
transgenic animals, we examined in greater depth the effect of PGC-1α on the 
transcription of the atrogin-1 gene. In fasting and various catabolic states, where there is 
decreased insulin/IGF-1 or insulin-resistance, the forkhead family of transcription factors, 
including FoxO3, become dephosphorylated, enter the nucleus, and activate transcription 
(12, 13, 43). FoxO3 activation alone is sufficient to cause dramatic muscle wasting in 
vivo (13). To investigate whether PGC-1α might affect FoxO3-dependent transcription, 
we analysed the effect of PGC-1α on the atrogin-1 promoter in adult mouse muscles.  
Tibialis anterior muscle fibers were electroporated with an atrogin-1 promoter-reporter 
construct (13) with or without constructs expressing PGC-1α and a constitutively active 
form of FoxO3, c.a.FoxO3A.  This mutant FoxO3 cannot be phosphorylated /inactivated 
by AKT, because it carries mutations in the three AKT phosphorylation sites (T32A, 
S253A, and S315A).  As shown in Fig 4a and reported previously (13), c.a.FoxO3 caused 
a dramatic (30-50 fold) induction of the atrogin-1 promoter, but coexpression of PGC-1α 
in these cells suppressed markedly this induction by FoxO3. Further strong evidence of 
the ability of PGC-1α to suppress FoxO3-dependent transcription was obtained in similar 
experiments using a synthetic FoxO3 reporter containing six concatemerized DAF16 
binding sites (Fig. 4a).  The ability of c.a.FoxO3 to bind to the atrogin-1 promoter was 
tested by chromatin immunoprecipitation (ChIP) assays in nuclei isolated from mouse 
skeletal muscle. As shown in Fig. 4b, c.a.FoxO3 electroporated into mouse muscle was 
found in complex with the atrogin-1 promoter. However PGC-1α strongly suppressed 
c.a.FoxO3 binding at this site (Fig.4b).  
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As found in the reporter studies (Fig.4a) and with ChIP (Fig.4b), electroporation of PGC-
1α together with c.a.FoxO3 caused a marked reduction in FoxO-dependent transcription.   
 
Because of this ability to block the transcription by FoxO3, we analysed whether PGC-
1α expression could also inhibit the rapid loss of muscle mass induced by FoxO3. Adult 
tibialis anterior muscles were electroporated with c.a.FoxO3 with or without PGC-1α.  
The muscle fibers overexpressing c.a.FoxO3 underwent marked atrophy, losing more 
than 40% of their cross section area in eight days, in accord with prior findings (13). In 
contrast, the coexpression of PGC-1α with FoxO3 blocked this response, and maintained 
fiber diameter close to that in the surrounding untransfected fibers (Fig. 4c). These results 
together demonstrate that PGC-1α protects against muscle atrophy at least in part by 





It is now clear that a specific program of transcriptional changes underlies the rapid 
atrophy of muscle seen in a wide variety of pathological states, ranging from denervation 
or disuse of a specific muscle, to fasting and systemic diseases (5, 7).  Based upon the 
findings presented here, it is clear that the PGC-1α coactivator is an important 
determinant of this transcriptional program and the extent of fiber atrophy.  First, the  
level of  PGC-1α was shown to decrease sharply in muscles early during atrophy induced 
by section of the motor neuron in mice, as well as by diabetes, renal failure, and cancer 
cachexia in rats.  This fall in PGC-1α expression with disuse is the mirror image of the 
increased expression after exercise (32-34), believed to be signaled by Ca2+ influx and 
calcineurin (30, 31).  However, the mechanism for the surprising fall in PGC-1α in 
diverse catabolic states is unclear and represents an important question for study. In 
related studies, we have also observed similar changes in levels of the homologous 
coactivator PGC-1β ((8), Z. Arany and B. Spiegelman, unpublished) which is not known 
to reflect contractile activity The systemic muscle wasting in these conditions appears to 
be triggered by insulin resistance and/or insulin-deficiency (44), glucocorticoids (45), 
and/or various monokines (46).  The marked reduction in PGC-1α mRNA in atrophying 
muscles occurs where FoxO factors are activated (13) and expressed at high rates (7). In 
related experiments, we observed a large fall in PGC-1α mRNA in rat muscle by one day 
after nerve section or complete inactivation with neurons intact (8).  In these different 
situations, the decrease in PGC-1α expression occurs early and precedes the rise in 
protein degradation and marked weight loss, and thus is sufficiently rapid to help signal 
the atrophy process.  
 
Importantly, we have found that when the levels of PGC-1α are maintained, either by use 
of transgenic expressionor by electroporation of this cDNAinto adult muscle fibers, 
muscles are protected to a large extent from the atrophy induced by denervation, fasting, 
or expression of FoxO3.  This protective effect can explain how exercise, by inducing 
expression of PGC-1α, can maintain muscle mass and retard atrophy, even in the face of 
circulating catabolic factors (14).  This new role for PGC-1α in influencing fiber size and 
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blocking atrophy complements its well-established role in determining fiber type (35), 
mitochondrial content and oxidative capacity (47-49), and other exercise-induced 
adaptations (32).  PGC-1α functions as a key sensor of muscular activity, and as shown 
here, its fall appears to play a key role in allowing the large induction of the critical 
ubiquitin ligases, atrogin-1 and MuRF-1, as well as another major atrogene, cathepsin L, 
the lysosomal hydrolase which presumably is important in the enhanced lysosmal 
proteolysis also seen in atrophying muscle (41)(Zhao et al, in preparation) (Fig. 5). 
 
The major signal that reglates postnatal growth of muscle is the IGF-1/PI3K/AKT 
pathway, which promotes protein synthesis by activating translation generally, but also 
retards protein degradation and the expression of various atrogenes (12, 13, 50) (Fig. 5).  
Overproduction of active AKT prevents atrophy especially through its ability to block the 
activation of FoxO1, 3, and 4 (2, 13).  Unlike IGF-1/AKT, PGC-1α, if overproduced, 
does not lead to a significant increase in muscle mass in transgenic mice (35) and when 
transfected into cultured muscle cells, does not stimulate overall protein synthesis 
(unpublished observations).  Nevertheless, PGC-1α clearly inhibits the atrophy induced 
by denervation or fasting, both of which involve FoxO-dependent transcription.  The 
inhibition of the profound atrophy and atrogene expression induced by electroporation of 
c.a.FoxO3 is noteworthy since this effect cannot be mediated by changes in AKT, and 
this action seems sufficient to account for PGC-1α’s ability to retard fiber atrophy.  
Furthermore, our findings with the promoter of atrogin-1 using chromatin 
immunoprecipitation (ChIP) and luciferase reporters indicate that PGC-1α somehow 
inhibits FoxO-dependent transcription.  By contrast, in liver PGC-1α positively interacts 
with FoxO1, important in the stimulation of transcription of genes for gluconeogenesis 
(51).  Since PGC-1α is a well-established coactivator of transcription, we cannot 
eliminate the possibility that its inhibitory action on the atrophy process is indirect. For 
example, PGC-1α may cause expression of an inhibitor of FoxO or the increased 
mitochondrial content or enhanced β-oxidative metabolism induced by PGC-1α may 
indirectly result in protection from atrophy. 
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The present findings can explain a number of well-established observations concerning 
the interactions of hormones and activity in the control of muscle size.  For example, it 
has long been known that the pale glycolytic fibers found typically in fast twitch muscles 
atrophy selectively in response to sepsis (21) or tumors (22, 23), fasting (18), or high 
levels of glucocorticoids (52).  Presumably, their differential susceptibility insures that in 
fasting and other stressful states, mobilization of amino acids from muscle protein occurs 
primarily from easily spared, less frequently used fibers (14).  The greater sensitivity of 
the type IIb fibers can be explained by their lower content of PGC-1α.  Accordingly, 
increased exercise can protect such fibers from glucocorticoids and can even induce 
muscle hypertrophy in fasted animals (14).  By contrast, the dark type I fibers high in 
PGC-1α content become sensitive to glucocorticoid-induced atrophy and show the 
greatest atrophy upon denervation when PGC-1α expression falls (24).  Thus, together 
with the exercise-induced production of IGF-1, the exercise-induced changes in PGC-1α 
in muscle seem to be critical factors by which contractile activity determines muscle size 




Animals and in vivo transfection experiments 
PGC1a transgenic mice and singenic controls were starved for 48 hours, then muscles 
were collected and frozen in liquid nitrogen. Disuse atrophy was induced by cutting 
sciatic nerve of PGC1 transgenic and control mice. After 12 days mice were sacrified, 
muscles collected, serial sectioned and stained for SDH. In vivo transfection experiments 
were performed by intramuscular injection of plasmid DNA in tibialis anterior muscle 
followed by electroporation as described (13). Muscles were removed at 8, 10, and 12 
days after transfection and frozen in liquid nitrogen for subsequent analyses.  
 
Gene expression analyses 
Total RNA was isolated from skeletal muscle tissue using the Trizol reagent (Invitrogen). 
For real-time PCR analysis, 1 µg of total RNA was reverse transcribed and the resulting 
cDNA used in semiquantitative PCR reactions with SYBR green dye on a 7300 real-time 
PCR system (ABI). Relative gene expression was calculated with the ΔΔCt method by 
normalization to 18S rRNA expression. 
 
Immunohistochemistry and Fiber Size Measurements. 
Mouse muscle fibers expressing HA-tagged or Flag-tagged proteins were stained in 
cryocross-sections fixed with 4% paraformaldehyde. Immunohistochemistry with anti-
HA polyclonal antibody (Santa Cruz) anti-Flag polyclonal antibody (Sigma) was as 
previously described (13). Muscle fiber size was measured in fibers transfected with the 
Foxo3 mutant with or whithout PGC-1α and in an equal number of untransfected fibers 
from the same muscle as described elsewhere (13). All data are expressed as the mean ± 
SEM. Comparison were made by using the student's t test, with p < 0.05 being considered 
statistically significant 
 
ChIP assay and promoter analysis. ChIP assay in adult skeletal muscles was performed 
using a Chromatin Immunoprecipitation (ChIP) assay kit (Upstate) according to the 
manufacturer’s instructions. Soluble chromatin was co-immunoprecipitated with anti-HA 
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antiserum (Santa Cruz), or an equal amount of IgG. After de-crosslinking of the DNA, 
samples were subjected to PCR using the following primers: atrogin1 (-1740 to -1537), 
Fw 5’-CTGGCAGGGAGGAGCCTAATGAATC, Rv 5’-
GGGAGTGGCAAAGCCGTCTC. This region of amplification contains FoxO binding 
sites for atrogin-1 promoter. The 3.5 kB atrogin-1 and the DBE reporters have been 
previously described (13). These constructs were co-transfected into tibialis anterior 
muscle with a renilla-luciferase vector (pRL-TK) to normalize for transfection efficiency 
and luciferase assays were performed by standard procedures in muscles removed 8 days 




This work was supported by grants from the NIH (XXXX to B.S. and DK6230701 to 
S.H.L.), the Muscular Dystrophy Association, National Space Biomedical Research 
Istitute and the Ellison Foundation to A.L.G, and from Telethon (S04009), AFM (11026) 




1. Bassel-Duby, R. & Olson, E. N. (2006) Annu Rev Biochem 75, 19-37. 
2. Glass, D. J. (2003) Nat Cell Biol 5, 87-90. 
3. Jackman, R. W. & Kandarian, S. C. (2004) Am J Physiol Cell Physiol 287, C834-
43. 
4. Lecker, S. H., Solomon, V., Mitch, W. E. & Goldberg, A. L. (1999) J Nutr 129, 
227S-237S. 
5. Lecker, S. H., Goldberg, A. L. & Mitch, W. E. (2006) J Am Soc Nephrol. 
6. Jagoe, R. T., Lecker, S. H., Gomes, M. & Goldberg, A. L. (2002) FASEB J 16, 
1697-1712. 
7. Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, 
S. R., Mitch, W. E. & Goldberg, A. L. (2004) FASEB J 18, 39-51. 
8. Sacheck, J. M., Hyatt, J.-P., Raffaello, A., Jagoe, T. T., Roy, R. R., Edgerton, V. 
R., Lecker, S. H. & Goldberg, A. L. (2006) FASEB J. 
9. Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A. & Goldberg, A. L. (2001) 
Proc Natl Acad Sci U S A 98, 14440-5. 
10. Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K., Nunez, L., Clarke, B. A., 
Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., Pan, Z. Q., 
Valenzuela, D. M., DeChiara, T. M., Stitt, T. N., Yancopoulos, G. D. & Glass, D. 
J. (2001) Science 294, 1704-8. 
11. Sacheck, J. M., Ohtsuka, A., McLary, S. C. & Goldberg, A. L. (2004) Am J 
Physiol Endocrinol Metab. 
12. Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., 
Gonzalez, M., Yancopoulos, G. D. & Glass, D. J. (2004) Mol Cell 14, 395-403. 
13. Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., 
Schiaffino, S., Lecker, S. H. & Goldberg, A. L. (2004) Cell 117, 399-412. 
14. Goldberg, A. L. (1968) Endocrinology 83, 1071-3. 
15. Zinna, E. M. & Yarasheski, K. E. (2003) Curr Opin Clin Nutr Metab Care 6, 87-
93. 
16. Alkner, B. A. & Tesch, P. A. (2004) Acta Physiol Scand 181, 345-57. 
17. Fluckey, J. D., Dupont-Versteegden, E. E., Montague, D. C., Knox, M., Tesch, P., 
Peterson, C. A. & Gaddy-Kurten, D. (2002) Acta Physiol Scand 176, 293-300. 
18. Li, J. B. & Goldberg, A. L. (1976) Am J Physiol 231, 441-8. 
19. Goldberg, A. L. & Goodman, H. M. (1969) J Physiol 200, 655-66. 
20. Dahlmann, B., Rutschmann, M. & Reinauer, H. (1986) Biochem J 234, 659-64. 
21. Tiao, G., Lieberman, M., Fischer, J. E. & Hasselgren, P. O. (1997) Am J Physiol 
272, R849-56. 
22. Baracos, V. E., DeVivo, C., Hoyle, D. H. & Goldberg, A. L. (1995) Am J Physiol 
268, E996-1006. 
23. Acharyya, S., Ladner, K. J., Nelsen, L. L., Damrauer, J., Reiser, P. J., Swoap, S. 
& Guttridge, D. C. (2004) J Clin Invest 114, 370-8. 
24. Herbison, G. J., Jaweed, M. M. & Ditunno, J. F. (1979) Arch Phys Med Rehabil 
60, 401-4. 
25. Falduto, M. T., Czerwinski, S. M. & Hickson, R. C. (1990) J Appl Physiol 69, 
1058-62. 
 18 
26. Lin, J., Handschin, C. & Spiegelman, B. M. (2005) Cell Metab 1, 361-70. 
27. Finck, B. N. & Kelly, D. P. (2006) J Clin Invest 116, 615-22. 
28. Soyal, S., Krempler, F., Oberkofler, H. & Patsch, W. (2006) Diabetologia 49, 
1477-88. 
29. Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M. & Spiegelman, B. M. 
(1998) Cell 92, 829-39. 
30. Handschin, C., Rhee, J., Lin, J., Tarr, P. T. & Spiegelman, B. M. (2003) Proc Natl 
Acad Sci U S A 100, 7111-6. 
31. Czubryt, M. P., McAnally, J., Fishman, G. I. & Olson, E. N. (2003) Proc Natl 
Acad Sci U S A 100, 1711-6. 
32. Taylor, E. B., Lamb, J. D., Hurst, R. W., Chesser, D. G., Ellingson, W. J., 
Greenwood, L. J., Porter, B. B., Herway, S. T. & Winder, W. W. (2005) Am J 
Physiol Endocrinol Metab 289, E960-8. 
33. Baar, K., Wende, A. R., Jones, T. E., Marison, M., Nolte, L. A., Chen, M., Kelly, 
D. P. & Holloszy, J. O. (2002) FASEB J 16, 1879-86. 
34. Russell, A. P., Feilchenfeldt, J., Schreiber, S., Praz, M., Crettenand, A., Gobelet, 
C., Meier, C. A., Bell, D. R., Kralli, A., Giacobino, J. P. & Deriaz, O. (2003) 
Diabetes 52, 2874-81. 
35. Lin, J., Wu, H., Tarr, P. T., Zhang, C. Y., Wu, Z., Boss, O., Michael, L. F., 
Puigserver, P., Isotani, E., Olson, E. N., Lowell, B. B., Bassel-Duby, R. & 
Spiegelman, B. M. (2002) Nature 418, 797-801. 
36. Price, S. R., Bailey, J. L., Wang, X., Jurkovitz, C., England, B. K., Ding, X., 
Phillips, L. S. & Mitch, W. E. (1996) J Clin Invest 98, 1703-8. 
37. Bailey, J. L., Wang, X., England, B. K., Price, S. R., Ding, X. & Mitch, W. E. 
(1996) J Clin Invest 97, 1447-53. 
38. Kettelhut, I. C., Pepato, M. T., Migliorini, R. H., Medina, R. & Goldberg, A. L. 
(1994) Braz J Med Biol Res 27, 981-93. 
39. Wing, S. S. & Goldberg, A. L. (1993) Am J Physiol 264, E668-76. 
40. Medina, R., Wing, S. S. & Goldberg, A. L. (1995) Biochem J 307, 631-7. 
41. Attaix, D., Mosoni, L., Dardevet, D., Combaret, L., Mirand, P. P. & Grizard, J. 
(2005) Int J Biochem Cell Biol 37, 1962-73. 
42. Furuno, K., Goodman, M. N. & Goldberg, A. L. (1990) J Biol Chem  265, 8550-7. 
43. Lee, S. W., Dai, G., Hu, Z., Wang, X., Du, J. & Mitch, W. E. (2004) J Am Soc 
Nephrol 15, 1537-45. 
44. Glass, D. J. (2005) Int J Biochem Cell Biol 37, 1974-84. 
45. Hasselgren, P. O. (1999) Curr Op Clin Nutr Metab Care 2, 201-5. 
46. Reid, M. B. & Li, Y. P. (2001) Respir Res 2, 269-72. 
47. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., 
Troy, A., Cinti, S., Lowell, B., Scarpulla, R. C. & Spiegelman, B. M. (1999) Cell 
98, 115-24. 
48. Mootha, V. K., Handschin, C., Arlow, D., Xie, X., St Pierre, J., Sihag, S., Yang, 
W., Altshuler, D., Puigserver, P., Patterson, N., Willy, P. J., Schulman, I. G., 
Heyman, R. A., Lander, E. S. & Spiegelman, B. M. (2004) Proc Natl Acad Sci U 
S A 101, 6570-5. 
49. St-Pierre, J., Lin, J., Krauss, S., Tarr, P. T., Yang, R., Newgard, C. B. & 
Spiegelman, B. M. (2003) J Biol Chem 278, 26597-603. 
 19 
50. Latres, E., Amini, A. R., Amini, A. A., Griffiths, J., Martin, F. J., Wei, Y., Lin, H. 
C., Yancopoulos, G. D. & Glass, D. J. (2005) J Biol Chem 280, 2737-44. 
51. Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., 
Kitamura, Y., Altomonte, J., Dong, H., Accili, D. & Spiegelman, B. M. (2003) 
Nature 423, 550-5. 






Figure 1.  Inhibition of PGC-1α expression in various types of muscle atrophy. a. Rat 
models of muscle atrophy; acute streptozotocin-induced diabetes mellitus, chronic renal 
failure induced by subtotal nephrectomy, cancer cachexia induced by Yoshida ascities 
hepatoma. Animal models were described in depth elsewhere (22, 36, 37).  Samples were 
taken at times where the muscles were undergoing rapid weight loss and PGC-1α assayed 
by quantitative PCR. b. Denervation by unilateral transection of the sciatic nerve in 
mouse. Results are expressed relative to mRNA levels in the contralateral enervated 
muscle. 
 
Figure 2. PGC-1α transgenic mice are protected from denervation and fasting induced 
muscle atrophy. a. Fiber size in control and denervated wild type mice. Left panel: 
succinate dehydrogenase staining of mock-transected (upper) and denervated (lower) 
tibialis anterior muscle. Right panel: fiber size distribution of tibialis anterior muscles. 
Red bars: denervated, Black bars: mock-transected. b. as in a, using MCK-PGC-1α 
transgenic mice. c. Mean cross-sectional area of denervated and control wild type and 
MCK-PGC-1α transgenic tibialis anterior muscles.  d. Mean cross-sectional area of 
tibialis anterior muscles from food deprived and fed wild type and MCK-PGC-1α 
transgenic animals. 
 
Figure 3. PGC-1α reduces transcription of key atrogenes involved in protein 
degradation. a. Expression of ubiquitin-ligases atrogin-1, MuRF1 and lysosomal 
hydrolase, cathepsin L, following denervation for 12 days, analyzed by rtPCR.  b. 
Expression of ubiquitin-ligases atrogin-1, MuRF1 and lysosomal hydrolase, cathepsin L, 
following food deprivation for 2 days, analyzed by rtPCR. c. Expression of genes 
involved in energy metabolism following 12 days of denervation. *, p<0.05 between 
control and transgenic mice, by Student’s t-test. 
 
Figure 4. PGC-1α suppresses FoxO3 action. a. Left panel. Plasmids bearing a luciferase 
reporter driven by the atrogin-1 promoter, constitutively active FoxO3A and PGC-1α 
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were electroporated into the intact tibialis anterior muscles of adult mice, and luciferase 
activity was measured in extracts from the muscles one week later. Right panel. as in left 
panel, but using a canonical FoxO sequence (DAF16) driving the luciferase gene. b. 
c.a.FoxO3 binding to a FoxO response element in atrogin-1 promoter is blocked by 
PGC1α. Muscles were collected eight days after c.a.FoxO3 transfection with or without 
FLAG-PGC-1α and ChIP assays were performed as described. c. Constitutively-active 
HA-tagged FoxO3A with or without FLAG-PGC1α were electroporated into the intact 
tibialis anterior muscles of adult mice. Muscles were harvested after 8 days, serially 
sectioned and subjected to immunohistochemistry (left panels) or fiber size quantification 
(right panel). 
 
Figure 5. Mechanisms for inhibition of atrophy and growth promotion by muscle 
activity.  With repeated muscle contractions, IGF-1 production by the muscle increases, 
which stimulates protein synthesis and fiber hypertrophy through activation of PI3K and 
AKT kinases.  AKT also causes phosphorylation and nuclear exclusion of FoxO 1, 3, and 
4, which suppresses atrogene expression and proteolysis. In addition, PGC-1α is induced, 
leading to increased production of mitochondria and a shift to slow, oxidative fibers. 
PGC-1α also inhibits transcriptional activity of FoxO3, which suppresses atrogene 
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